All News
Filter News
Found 6,662 articles
-
Compugen to Participate in Two Upcoming April 2024 Investor Conferences
4/3/2024
Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will participate in the following upcoming investor conferences in April.
-
Opthea Appoints Sujal Shah to the Board of Directors
4/3/2024
Opthea Limited, a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, announced the appointment of Sujal Shah to the Company’s Board of Directors, effective April 4, 2024.
-
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
4/2/2024
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.
-
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
4/1/2024
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Gilead Sciences’ Vemlidy on Thursday secured a label expansion from the FDA, allowing the antiviral drug’s use to treat chronic hepatitis B in pediatric patients aged six years and older.
-
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
3/28/2024
Xilio Therapeutics, Inc. announced that it has entered into a securities purchase agreement with certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital.
-
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
3/28/2024
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
-
Advanced Therapy Medicinal Products CDMO Industry is Rising Rapidly
3/28/2024
According to latest study, the global advanced therapy medicinal products CDMO Market size was valued at USD 6.10 billion in 2023 and is projected to reach USD 34.53 billion by 2033
-
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
3/28/2024
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has approved the supplemental new drug application for Vemlidy® 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
-
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
3/28/2024
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Colleen Sjogren as Chief Commercial Officer.
-
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
3/28/2024
Galapagos NV publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm and 3:00 pm, respectively, at the registered office of the Company.
-
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
3/28/2024
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023.
-
Nucleus RadioPharma Announces Appointment of Chris McDonald from Kite, a Gilead Company, to Board of Directors
3/27/2024
Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Chris McDonald, Global Head of Technical Operations at Kite, a Gilead Company, to its Board of Directors.
-
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
3/27/2024
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2023, along with a corporate update.
-
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
3/26/2024
Cellares, a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization, announced the addition of Christi Shaw to its Advisory Board.
-
Echosens Appoints Dr. Victor De Lédinghen as Chief Medical Officer
3/26/2024
Echosens announced the appointment of Victor de Lédinghen, MD PhD, as the company's new Chief Medical Officer.
-
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
3/26/2024
Galapagos NV announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.
-
Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors
3/26/2024
Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D. has been added to the Board of Directors.
-
Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.
-
Gilead Sciences Announces Completion of Acquisition of CymaBay
3/22/2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.